Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b trial of Nitric Oxide (UNO) in combination with PD-1 inhibitor therapy subjects with prior exposure to anti-PD-1 antibody that have either progressed, not achieved a response, or have prolonged stable disease

Next Previous
Trial Profile

A Phase 1b trial of Nitric Oxide (UNO) in combination with PD-1 inhibitor therapy subjects with prior exposure to anti-PD-1 antibody that have either progressed, not achieved a response, or have prolonged stable disease

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitric oxide (Primary) ; Programmed cell death 1 receptor antagonists
  • Indications Solid tumours
  • Focus Adverse reactions

Most Recent Events

  • 10 Jun 2024 New trial record
  • 03 Jun 2024 According to a Beyond cancer media release, the protocol for this study has been submitted to the Israeli Ministry of Health (IMOH) and upon regulatory approval. Subjects enrolled in the Phase 1b trial will be treated with the UNO + anti-PD-1 combination upon completion of the Phase 1a trial. The study design was unveiled at 2024 American Society of Oncology Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top